NCT05346484View on ClinicalTrials.gov

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

November 30, 2026

Conditions
Solid TumorSolid CarcinomaSolid Tumor, AdultMetastatic CancerAdvanced Solid TumorCholangiocarcinomaBile Duct Cancer
Interventions
BIOLOGICAL

CF33-hNIS

CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)

BIOLOGICAL

Pembrolizumab

Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).

DRUG

Modified FOLFOX

"28 day cycle of:~* Leucovorin calcium/folinic acid~* Fluorouracil~* oxaliplatin"

Trial Locations (12)

3065

RECRUITING

St. Vincent's Hospital, Fitzroy

4215

RECRUITING

Tasman Oncology Research, Southport

22031

RECRUITING

NEXT Oncology, Fairfax

33136

RECRUITING

University of Miami, Miami

45219

RECRUITING

University of Cincinnati, Cincinnati

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

49503

RECRUITING

Corewell Health, Grand Rapids

72762

RECRUITING

Highlands Oncology, Springdale

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

91010

RECRUITING

City of Hope Medical Center, Duarte

85724-5024

RECRUITING

University of Arizona Cancer Center, Tucson

92093-0698

RECRUITING

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
lead

Imugene Limited

INDUSTRY